DCLK1 and pancreatic neoplasm: Ferguson et al. identified 29 significantly decreased (p < 0.05, Log2FC < −0.5) phosphorylation sites on 20 different proteins, mainly involved in cell motility, after treatment of human pancreatic cancer organoids with DCLK1-IN-1 [48], whereas DCLK1-IN-1 treatment in colorectal cancer cells resulted in the downregulation of 63 phosphorylation sites on 37 proteins [49].